BFM
SMMT icon

Boothbay Fund Management’s Summit Therapeutics SMMT Stock Holding History

Boothbay Fund Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-484,000
Closed -$847K – 2252
2023
Q1 		$847K Buy
+484,000
New +$1.32M 0.02% 1068

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Boothbay Fund Management's SMMT Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 53,964 shares worth $1.02M. The stake represents 0.01% of the portfolio and ranks #936 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in SMMT as recently as Q1 2025.

Boothbay Fund Management first reported a position in SMMT in Q1 2022 and has held it in 10 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Boothbay Fund Management held 53,964 shares of Summit Therapeutics worth $1.02M as of Q1 2026.
  • Summit Therapeutics was a new Boothbay Fund Management position in Q1 2026.
  • Summit Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #936 holding.
  • Boothbay Fund Management first reported a position in Summit Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.